Once again, the positive Anavex science data.
I watched and listened to Dr. Hammond’s presentation on the status of Anavex Life Science Corps’ clinical and scientific data at the Needham conference. No, no new clinical results were released; all data have been previously presented.
As always, because I have a moderate AVXL holding, I wanted, again, to discover any negative data I’ve not factored into my long-term holding of my Anavex shares — all of which is dependent upon positive clinical outcomes.
I looked closely, but found nothing negative. In every one of the several clinical trials of blarcamesine (Anavex 2-73) aimed at central nervous system (CNS) diseases, no adverse events (AEs), side effects. So very different from existing and candidate CNS drugs; virtually all of which have AEs that inhibit or restrict therapeutic uses. Once again, as always before, blarcamesine proved (in humans, not just animal models) to be utterly safe, even at the highest therapeutic doses in the human trials. So rare for drugs acting in the CNS.
Safety was great. But were there therapeutic efficacies? Did the drug actually produce favorable therapeutic outcomes? Were those merely by chance, or were they statistically significant; actually caused by the drug, not mere chance? P-values in every case showed statistical significance. Simply, blarcamesine worked. It either stopped the progression of the disease being treated, or even reversed the pathological progression.
Safety and efficacy. I’m confident that with the completion of the on-going Phase 3 clinical studies, projected to be in the last half of this year, blarcamesine will be granted sales and therapeutic use authorizations. A year from now, Anavex Life Sciences Corp will be a recognized major pharmaceutical in the making.
Which means that I’ll never be selling a share of my AVXL position. I’m in my mid-70s. I’ll be rewarded in a few years with Anavex dividends. The shares will pass to my estate’s beneficiaries and to the philanthropies I will designate. Most importantly, the lives of tens of millions who would otherwise suffer severely from various CNS (and other) diseases will be spared such suffering and economic disaster.
